Current Status of Glucagon-like Peptide-1 Receptor Agonists in Metabolic Dysfunction-associated Steatotic Liver Disease: A Clinical Perspective.

placebo 22%), although this did not reach statistical significance. 53 Survodutide is generally well tolerated in patients with compensated or decompensated cirrhosis, of which more than 80% are diagnosed with MASLD.

also in 111,027 other papers